Seqens Seqens

X
Veranova: A CDMO that manages complexity with confidence.
  • A company that focuses on developing, manufacturing and marketing of branded generic & specialty drugs in respiratory, dermatology, anti-inflammatory, anesthetics, anti-infectives, anti-nauseants, anti-emetics, anti-ulcers, NSAIDs and ophthalmic therapeutic areas is looking for suppliers of Tapinarof API for development purposes. The suppliers must support this enquiry with CoA.
    23 Apr 2024

    Comment Comment

    Reply text-arrow

    A research-based company that focuses on diabetes, oncology, immunology, and other non-communicable diseases is looking for suppliers of Avatrombopag (3 kg - 4 kg/ year) API for commercial purposes. The suppliers must support this enquiry with USDMF & CoA.
    23 Apr 2024

    Comment Comment

    Reply text-arrow

  • A company that focuses on manufacturing of tablets, creams & ointments, injectables and sterile ophthalmic is looking for suppliers of BP/ Ph. Eur./ USP/IP/JP Grade Papaverine Hydrochloride API for development purposes. The suppliers must support this enquiry with open part DMF, GMP & CoA.
    23 Apr 2024
    A pharmaceutical company that focuses on the development and manufacturing of granules, pellets, capsules & tablets is looking for suppliers of Dutasteride (5 kg - 10 kg) API for commercial purposes. The suppliers must support this enquiry with CEP, CADIFA & CoA.
    22 Apr 2024
  • A CRO or CDMO that specializes in organic synthesis, process development and analytical chemistry of various APIs for human and veterinary use is looking for suppliers of Halofuginone HBr API for development purposes. The suppliers must support this enquiry with CoA.
    22 Apr 2024
    A Group of companies that focuses on manufacturing, development & distribution of various finished formulations is looking for suppliers of Carbocysteine (105 kg) API for commercial purposes. The suppliers must support this enquiry with CEP, DMF and CoA .
    22 Apr 2024
  • A large pharmaceutical company that devotes itself to R&D, production, marketing and sales of active pharmaceutical ingredients and pharmaceutical intermediates is looking for suppliers of Citicoline (1g/ dose) Sachet- 10 ml pack for commercial purposes. The required quantity is MOQ. The supplier must support this enquiry with EAEU.
    18 Apr 2024
    A company that focuses on manufacturing and distribution of various finished formulations used in surgery, dermatology, orthopedics, pediatrics, cardiology, gynecology, therapy and other areas of modern medicine is looking for suppliers of various finished formulation for commercial purposes. The required quantity is 10,000 packs.
    1. Clindamycin 100 mg + Clotrimazole 200 mg suppositories.
    2. Clindamycin 100 mg + Clotrimazole 100 mg + Tinidazole 100 mg suppositories.
    3. Metronidazole 500 mg + Neomycin sulfate 65 000 IU + Nystatin 100 000 IU suppositories.
    4. Neomycin 83 mg + Metronidazole 500 mg + Clotrimazole 100 mg suppositories.
    5. Metamizole 400 mg + Drotaverine hydrochloride 40 mg + Caffeine 60 mg Tablets.
    6. Ibuprofen 400 mg + Drotaverine hydrochloride 80 mg Tablets.
    7. Drotaverine 80 mg + Paracetamol 500 mg Tablets.
    8. Drotaverine 80 mg + Mefenamic acid 250 mg Tablets.
    9. Dicycloverine 10 mg + Mefenamic acid 250 mg Tablets.
    10. Dicycloverine 20 mg + Paracetamol 500 mg + Mefenamic acid 250 mg Tablets.
    11. Orphenadrine citrate 35 mg + Mefenamic acid 250 mg Tablets.
    12. Orphenadrine citrate 50 mg + Aspirin 770 mg + Caffeine 60 mg Tablets.
    13. Hyoscine butylbromide 10 mg + Ketoprofen 100 mg Tablets.
    14. Hyoscine butylbromide 20 mg + Ibuprofen 400 mg + Caffeine 50 mg Tablets.
    15. Hyoscine butylbromide 20 mg + Ibuprofen 400 mg Tablets.
    16. Hyoscine butylbromide 10 mg + Metamizole 250 mg Tablets.
    17. Hyoscine butylbromide 10 mg + Paracetamol 500 mg Tablets.
    16 Apr 2024
  • A global pharmaceutical company that focuses in research, development and manufacturing of generic pharmaceuticals and biosimilars is looking for suppliers of various finished formulations for commercial purposes. The supplier must support this enquiry with dossiers.
    1. Oxycodone HCl (5 mg) Capsules. The required quantity is 60,000 units/ year.
    2. Oxycodone HCl (10 mg) Capsules. The required quantity is 60,000 units/ year.
    3. Oxycodone HCl (20 mg) Capsules. The required quantity is 60,000 units/ year.
    4. Oxycodone HCl (40 mg) Capsules. The required quantity is 60,000 units/ year.
    5. Oxycodone HCl (80 mg) Capsules. The required quantity is 60,000 units/ year.
    08 Apr 2024
    A company with 3 divisions which focuses on manufacturing and development of various finished formulations is looking for suppliers of Various RLDs for development purposes.
    1. Rivaroxaban (2.5 mg/ 10 mg/ 15 mg) Tablets
    2. Rosuvastatin Calcium (5 mg/ 10 mg/ 20 mg/ 40 mg) Tablets
    3. Nortriptyline (10 mg/ 25 mg/ 50 mg/ 75 mg) Capsules
    4. Febuxostat (40 mg/ 80 mg) Tablets
    5. Betahistine (8 mg/ 16 mg) Tablets
    6. Dapagliflozin (5 mg/10 mg) Tablets
    7. Empagliflozin (10 mg/ 25 mg) Tablets
    8. Vonoprazan Fumarate (10 mg/ 20 mg) Tablets
    04 Apr 2024
  • A company that provides a range of full R&D pharmaceutical services and drug delivery solutions is looking for GMP & EMEA/ USFDA Certified CDMO to manufacture powders & granules. The required packaging is PET-glass bottle/ sachet stick pack. The country of distribution is Europe & United States. The geographical preference for service provider is Canada, EMEA & United States.
    19 Apr 2024

    Comment Comment

    Reply text-arrow

    A company that focuses on development of innovative prescription products for aesthetic medicine and medical dermatology is looking for CMO to manufacture Liniment for the treatment of Crow’s feet and hyperhidrosis. The required packaging is 1 ml in dropper. The project launch time is in 2026. The required quantity is 10 batches of 100 kg. The country of distribution is United States. The geographical preference for service provider is United States.
    22 Feb 2024
  • A company based in United States that focuses providing solutions in areas specifically defense, intelligence, health & bioscience, transport, energy and critical infrastructure is looking for GMP certified CDMO for intravenous injectables. The country of distribution is United States.
    09 Feb 2024
    A CMO that focuses on manufacturing, licensing & marketing of various OTC & Rx finished formulations is looking for a GMP certified CDMO for Tech Transfer of Solid, Liquid and Semi-Solid finished formulations. The projected annual manufacturing volume is 30 MT – 1000 MT. The country of distribution is Europe & United Kingdom and the geographical preference for service provider is Europe.
    20 Jan 2024
  • A CDMO that focuses on manufacturing, development & distribution of various non-sterile oral dosage forms is looking for suppliers of Ph. Eur. Grade Dichloromethane (6 Tons) Excipient for commercial purposes. The supplier must support this enquiry with CEP & DMF.
    23 Apr 2024
    A U.S.- domiciled publicly traded generics and specialty pharmaceutical company is looking for suppliers of USP Grade Sodium Deoxycholate Excipient for development purposes. The supplier must support this enquiry with GMP & CoA.
    22 Apr 2024
  • A company that deals in the import, export and distribution of various pharmaceutical products is looking for suppliers of Pharma Grade Coco Diethanolamide (25 kg) Excipient for commercial purposes. The supplier must support this enquiry with CoA.
    20 Apr 2024
    A company that provides a range of full R&D pharmaceutical services and drug delivery solutions is looking for suppliers of Various Excipients for development purposes. The supplier must support this enquiry with EMEA/US-FDA registration & CoA.
    1. Capric acid Excipient
    2. Caprylic acid Excipient
    3. Sodium taurocholate Excipient
    4. Sodium Lauryl Sulfate Excipient
    5. Sodium glycocholate Excipient
    19 Apr 2024

Interviews #SpeakPharma

  • “Athena’s R&D prowess is its key differentiator, with our India unit bringing in excellent knowledge”
    This week, SpeakPharma interviews Alexandre Williams, owner and director of Athena Pharmaceutiques, which is a trusted partner of choice to source differentiated branded generics in the pharmaceutical sector. Williams discusses the importance of research and development (R&D) to deliver cutting edge medical solutions to the international market, and the strategy behind choosing India to expand its R&D operations.  🔑 HIGHLIGHTS// branded generics/ innovation/ forward thinking/ CDMO/ France/ India Athena Pharma has come a long way since it was first spun off from its parent company — Ethypharm — in 2011. The growth has been particularly remarkable over the last three years. Tell us how the company has managed to scale new heights during and post the Covid-19 pandemic? We’ve been expanding operations in emerging markets since 2012, while also not ignoring developed markets. In 2017, we launched products in Europe, Canada, and the UK among other markets. So, we’ve been on a roll. Covid had, in fact, a small impact on our activity. It did slow down some R&D and expansion projects. However, given our broad portfolio with allergy, anti-emetic and pain relief products, we saw an increase in sales during the pandemic. In fact, 2020 was a big year for us. We acquired our first European factory in France — Athena IPS, set up our first office in Canada, and bought an effervescent technology. In 2022, we acquired the brand Secnol (secnidazole) and launched a new R&D facility in India. Compared to Covid, we saw the European energy inflation crisis as a bigger threat, given the continent’s reliance on Russia for energy. Russia’s invasion of Ukraine and the expected sanctions on Russian imports meant that energy costs were going to skyrocket and create a massive turmoil in the supply chain. Those repercussions were felt by the market and our clients. Our growth is fueled by our extensive portfolio of products. We have a huge number of launches planned in Brazil and pretty much every emerging market. Indeed, we will see over 100 new launches in the next two years. 🔑 HIGHLIGHTS// EU/ UK/ factory in France/ new office in Canada/ new R&D unit in India/ effervescent tech/Secnol acquisition How is the market for branded generics growing? How is Athena creating a differentiation within this market to prolong the life of well-established products through improved drug delivery systems? As mentioned, the pandemic was a booster for the branded generics market. As healthcare systems the world over scrambled to meet needs, accessibility and affordability that come with branded generics made them even more crucial. Furthermore, global supply chain disruptions led to a shift toward manufacturing locally and regionally produced branded generics. India has emerged as the largest generic supplier in the world. And with its growing population, the demand for affordable medication has also grown. Branded generics are best supported with improved formulations. By offering a better, different or new product, our partners can market differentiated products that are set apart from competition. The differentiation must really bring an improvement in terms of delivery, compliance, taste or dosing. Only real lifecycle advantages make a difference, but it also must be cost effective to allow our partners to push sales of these new brand generics. 🔑 HIGHLIGHTS// pandemic boosted branded generics market/ India emerged as largest generic supplier How important has R&D been to the company’s objective of delivering cutting-edge drugs? What steps have to be undertaken to ensure Athena’s commitment and dedication to R&D? Innovation has always been central to Athena’s DNA, right from our humble beginnings. The mission was to leverage great research and development (R&D) to deliver cutting edge medical solutions to the international market. We have invested steadily since our inception, including an investment in 2021 that led to opening up of our French R&D center. A year later, our new R&D center came up in Mumbai, adjacent to our Indian factory. Personnel is key and I must say that I am highly proud of our R&D team. Building a good team takes time and effort. No R&D department can function without the right people. 🔑 HIGHLIGHTS// innovation/ team work/ right people Athena has expanded its global presence (in markets like Brazil, Canada and China) in recent years. How have these expansions contributed to growth? Different geographies come with different situations, needs, demographies, and healthcare challenges. This forces us to adapt our technology to create products of interest in each of those territories. When we successfully pull off a product lifecycle in one market, we can take what we learned and make that product a huge success in other markets. For instance, in Canada we developed a generic zolpidem tablet for insomnia that disintegrates under the tongue. We then adapted it and positioned it as branded generic for Latin America and Europe and saw great success. 🔑 HIGHLIGHTS// different geographies — different needs How have dosage forms like oro-dispersible and modified release formulations performed? Have you added more drugs to these dosage forms? Oro-dispersible tablets (ODTs) are like conventional tablets with super disintegrants that dissolve in the mouth within minutes. ODTs have made it easy to administer medication, especially in pediatric, geriatric, and mental illness populations. This makes them a very popular dosage form. Improved patient compliance, rapid onset of action, and improved stability are some of the advantages we’ve seen. Athena’s Fastmelt technology has rendered it a leader in the ODT space. Modified drug release protracts the drug’s release into the bloodstream or to a specific target and this means they can be taken at less frequent intervals. We’ve seen an increase in patient convenience, compliance, and thereby improved efficacy. Sustained release (SR) products sustain the level of a drug in the bloodstream and reduce adverse effects. Indeed, we had developed many ODTs, taste masked and SR products. But what amazes me is that every time you are afraid that those matured technologies will become outdated, they don’t, and we have endless new developments to be carried out. 🔑 HIGHLIGHTS// ODTs for pediatric, geriatric, and mental illness/ SR drugs sustain level in bloodstream, reduce side effects What are some of the fastest growing drug release mechanisms? How is effervescent technology performing? As I mentioned, we are seeing speedy growth in drug delivery technologies. Fixed dose combinations are products of two or more drugs in a single dose. The simpler dosing schedule leads to excellent patient compliance, and it is among the fastest growing drug release mechanisms. Effervescent technology is widely used in Europe, and worldwide it is used to deliver vitamins. The technology is of particular interest when it comes to products that need to be solubilized and drugs that absolutely need to be taken with water. However, effervescent technology is underdeveloped in emerging markets and only used for over-the-counter (OTC) or food supplement products. There are many new formulations that can use effervescent technology, so we can easily expand. 🔑 HIGHLIGHTS// effervescent tech for vitamins/ yet to pick up in emerging markets What are some growth plans of Athena? Where do you see the company in the next five years? Our new target markets for the coming years are China and the US, where we aren’t as active at present. As far as growth goes, the most critical aspect is identifying the product that is to be developed. So, our goal in the coming years is to enrich our portfolio of products that bring real value to people and their quality of life. Ideas are welcome! 🔑 HIGHLIGHTS// China/ USA/ expand portfolio In terms of drug delivery technologies, Athena has come up with some groundbreaking solutions. Could you please tell us how these may be game-changers in the lives of patients? These days, there is a lot of talk about revolutionary biotechnologies like ARNm (advances in radiotherapy and nuclear medicine) and CAR-T therapies, which specifically target and eliminate cancer cells more effectively. But we should not underestimate the crucial role our drug delivery technologies play, particularly in enhancing medication acceptance and compliance. They hold immense potential and remain an integral part of the healthcare landscape because we offer cost-effective and impactful solutions that improve patient outcomes. 🔑 HIGHLIGHTS// enhancing medication acceptance and compliance/ cost-effective and impactful solutions Can artificial intelligence (AI) and machine learning help in discovering new drug delivery technologies? If so, then how? They can certainly help in pharmacodynamics (effects of drugs and the mechanism of their action). In the in vivo vitro correlation, which is the predictive mathematical model that describes the relationship between the in vitro property of an oral dosage form and the corresponding in vivo response, Al can help gain a better understanding of the drug’s release or dissolution and the amount absorbed.  AI can help optimize and perhaps even individualize timing and dosage. It can analyze patient data, health records, geographical locations, medical literature, and patient demographics to match patients for clinical trials and monitor the trials for adverse events. Such real-time analysis can increase patient safety and help researchers assess how individual patients respond. It can help design formulations and select which technology serves the patient best. The use of AI will be massive, and we are just starting to use it. 🔑 HIGHLIGHTS// pharmacodynamics/ optimize and perhaps even individualize timing and dosage/ patient safety What were the factors that helped Athena choose India for its expansion, particularly for R&D? R&D power is really what makes Athena different, and it is thanks to our Indian staff who are experienced and well trained in pharmaceutical development. So, we chose India mainly for excellence in drug delivery and knowledge of pharmaceutical development. And not just for cost-effectiveness. The Indian skill and competence are enhanced by the fact that Athena is active in so many markets from Europe and Canada to Brazil, Russia, and Asia. So, competence and experience required in those pharmaceutical markets is being acquired by our Indian personnel. The country is also doing a lot to ease foreign entry into its pharmaceutical industry like reducing timelines for facility approval. 🔑 HIGHLIGHTS// India: Excellence in pharma knowledge for DDS development

    Impressions: 121

    https://www.pharmacompass.com/speak-pharma/athena-s-r-d-prowess-is-its-key-differentiator-with-our-india-unit-bringing-in-excellent-knowledge

    19 Apr 2024

Data Compilation & Company Tracker #PharmaFlow

  • FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big
    In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molecules. Oligonucleotides are essentially short, single strands of DNA or RNA that modulate gene expression. There are various oligonucleotide therapy (ONT) agents (such as antisense, deoxyribozymes, siRNA and CRISPR/Cas) that offer promising therapeutic tools.A variation of gene therapy, oligonucleotide gene therapies (OGTs) are manufactured using synthetic oligonucleotides. These therapies are designed to enter cells. ONTs act like tools that can fine-tune the behavior of certain genetic instructions, and are therefore often designed to treat rare and genetic diseases and cancers. Sometimes, they may be delivered into cells through lipid nanoparticles or adeno-associated viruses (AAV), halting the translation of a specific protein. Oligonucleotides have also revolutionized vaccine development through the creation of nucleic acid vaccines, such as mRNA vaccines.The first oligonucleotide drug, known as fomivirsen, was approved by the US Food and Drug Administration (FDA) back in 1998. It was developed by Ionis Pharmaceuticals (then known as Isis Pharmaceuticals), and was approved to treat a rare eye disease. However, ONT approvals have picked up since 2016. Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency (EMA) and a majority of them treat orphan and rare diseases.In 2023, FDA approved four ONTs — AstraZeneca-Ionis’ Wainua (eplontersen), Novo Nordisk owned Dicerna Pharmaceuticals’ Rivfloza (nedosiran), Biogen-Ionis’ Qalsody (tofersen) and Iveric Bio’s Izervay (avacincaptad pegol).In 2021, the global ONT market size was estimated to be US$ 18.2 billion. It is expected to increase to US$ 51.4 billion by 2029, growing at a compounded annual rate (CAGR) of 13.85 percent. Similarly, the market for oligonucleotides synthesis (or the process of producing oligonucleotides) was estimated at US$ 7.7 billion globally in 2022 and is expected to grow 11.8 percent CAGR to reach US$ 16.4 billion by 2030. Some of the bigger players in oligonucleotides synthesis are Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins, Agilent, Bio-Synthesis, EUROAPI, Eurogentec, STA Pharma, and Bachem.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available)ONTs address neuro disorders; four ONTs bring in US$ 1.24 bn for AlnylamONTs are widely applied to treat neurodegenerative diseases, such as Duchenne muscular dystrophy (DMD). Multiple ONTs have been approved in Europe and the US for DMD, such as Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Amondys 45 (casimersen) from Sarepta and NS Pharma’s Viltepso (viltolarsen). Last year, Ionis bagged two approvals in the space. FDA approved its Biogen-partnered therapy Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS). The agency also approved AstraZeneca and Ionis’ drug Wainua (eplontersen), rendering it as the first self-administered treatment for a rare nerve damage disease, known as hereditary transthyretin amyloidosis (ATTR-PN). Analysts estimate global peak sales for Wainua to come in at US$ 750 million for ATTR-PN alone. The drug is also being tested for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare heart muscle disorder.Alnylam Pharmaceuticals has also successfully brought four ONTs to market in recent years — Onpattro (patisiran) and Amvuttra (vutrisiran) for rare nerve diseases, and Givlaari (givosiran) and Oxlumo (lumasiran). Givlaari has been approved to treat acute hepatic porphyria (a liver enzyme deficiency) while Oxlumo treats primary hyperoxaluria (a disorder characterized by increased urinary oxalate excretion). The four ONTs brought in US$ 1.24 billion for Alnylam in 2023.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Novartis buys rights to siRNA therapy, GSK bets big on ONT pipeline through dealsAfter Alnylam discovered inclisiran (Leqvio), Novartis acquired global rights to the therapy in a US$ 9.7 billion deal. Leqvio was the first FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction. It brought in US$ 355 million for Novartis in 2023.GSK has increasingly been investing in its ONT pipeline. The British pharma has promised over US$ 5 billion in upfront and milestone payments in multiple deals. In February, GSK exercised its option to license Elsie Biotechnologies’ discovery platform to find and develop novel ONTs. GSK has also entered a discovery collaboration with Wave Life Sciences.Last July, Japanese drugmaker Astellas Pharma completed its approximately US$ 5.9 billion buyout of New Jersey-headquartered Iveric Bio. Iveric focuses on retinal diseases and the deal gives Astellas drug candidates to treat about 160 million people with eye ailments. Subsequently, in August, Iveric’s Izervay (avacincaptad pegol) was approved by the FDA as a new treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).After Novo Nordisk acquired RNAi technology company Dicerna Pharmaceuticals for US$ 3.3 billion in 2021, the latter’s once-monthly RNAi therapy Rivfloza (nedosiran) saw FDA approval last October. Rivfloza was okayed for children nine years and older to treat a rare genetic condition that affects the kidneys, known as primary hyperoxaluria type 1 (PH1).View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Ionis tees up NDAs for rare disease treatments after two late-stage trial winsThe industry is looking for cures to a wide spectrum of diseases like cancer (such as melanoma, pancreatic, liver, glioblastoma, breast and ovarian cancer), cystic fibrosis, Alzheimer’s disease, Parkinson’s disease, hepatitis B, asthma, Rett syndrome, non-alcoholic steatohepatitis, and IgA nephropathy through its research on ONTs.In January, Ionis announced late-stage results wherein its RNA-targeted hereditary angioedema (HAE) candidate, donidalorsen, significantly reduced the rate of HAE attacks in patients treated every four weeks and patients treated every eight weeks. The California-based biotech is readying a new drug application (NDA) to submit to the FDA. HAE is a rare and life-threatening genetic disease that causes unpredictable and frequent severe swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat. This year, Ionis’ olezarsen was granted fast track designation by the FDA for the rare genetic disease familial chylomicronemia syndrome (FCS). Last September, olezarsen had met its primary endpoint of reducing abnormally high levels of triglycerides in a late-stage trial in patients with the metabolic disorder. Currently, there are no FDA-approved treatments for this condition. If okayed, olezarsen is likely to bring in US $849 million in sales for Ionis by 2032.In March, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in certain adult patients with myelodysplastic syndromes. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024, for Geron’s NDA for imetelstat. It is among the most anticipated drug launches this year.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Our viewDeveloping ONTs is a field fraught with challenges, such as toxicity and drug delivery. There are safety concerns as well as concerns around delivering the therapy. However, technological breakthroughs and collaborations between pharma firms and contract research organizations that focus on drug delivery are continuously working towards addressing these challenges. All in all, we foresee exciting times ahead for ONTs.  

    Impressions: 1904

    https://www.pharmacompass.com/radio-compass-blog/fda-approves-four-oligonucleotide-therapies-in-2023-novartis-gsk-novo-bet-big

    #PharmaFlow by PharmaCompass
    21 Mar 2024

Monthly Stock Recap #PipelineProspector

  • Pipeline Prospector March 2024: FDA approves pathbreaking NASH drug from Madrigal, two meds for PAH
    March was clearly a month of drug approvals, as the US Food and Drug Administration (FDA) went on an overdrive, green-lighting several therapies before the close of the first quarter (Q1 2024). Amongst them was the first drug to treat non-alcoholic steatohepatitis (NASH) and a breakthrough therapy that treats pulmonary arterial hypertension (PAH).However, the buoyancy in drug approvals didn’t play out in the stock markets and most pharma indices witnessed a marginal dip. The Nasdaq Biotechnology index (NBI) fell marginally (-0.43 percent) to 4,429.97 from 4,449. The SPDR S&P Biotech ETF index (XBI) dropped 4.6 percent to 94.89 after ending February at 99.44. And the S&P Biotechnology Select Industry index (SPSIBI) was down by 3.4 percent from 7,662.14 to 7,402.47 in March.In deals, AstraZeneca bought two companies, shoring up its cancer and rare disease pipelines. The Anglo-Swedish drugmaker first bought France’s Amolyt, which focuses on rare endocrine diseases, for a total of US$ 1.05 billion and then acquired next-generation cancer drugmaker Fusion Pharmaceuticals for around US$ 2 billion. AstraZeneca’s stock was up 4.6 percent in March. Novo Nordisk (stock up 4.8 percent) agreed to acquire Cardior Pharmaceuticals for up to US$ 1.1 billion in order to boost its pipeline for cardiovascular diseases.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel)FDA okays first drug for NASH; Wegovy approved as med to reduce heart risksFor quite some time, the drug development field for the liver condition non-alcoholic steatohepatitis (NASH) has been a graveyard for failed programs. In March, the field celebrated a hurrah moment when Madrigal Pharmaceuticals (stock up 6 percent) won the race to have the first NASH treatment approved by the FDA. Madrigal’s oral drug Rezdiffra (resmetirom) treats adults with NASH, a disease that causes histologic liver damage and occurs in patients who are not alcoholics and are often obese or have type 2 diabetes. The approval has opened a multi-billion dollar opportunity for Madrigal.The GLP-1 agonist drugs that are used to treat diabetes and obesity have shown heart-related benefits too in clinical trials. Last month, FDA approved Novo Nordisk’s Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in obese or overweight adults with cardiovascular disease (CVD). The move makes Wegovy the first weight-loss medication that is also approved to help prevent life-threatening cardiovascular events. The approval was hailed as a major advancement in public health.Another significant FDA approval was granted to Akebia’s anemia drug, vadadustat. After being turned down in March 2022, Akebia has now been approved to treat anemia caused by chronic kidney disease (CKD) in dialysis patients.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) FDA okays two meds for PAH; Italfarmaco’s Duvyzat approved for DMDFDA approved a breakthrough therapy from Merck, known as Winrevair (sotatercept-csrk), to treat adults with hypertension that is caused by constriction of the arteries in the lungs, known as pulmonary arterial hypertension (PAH). The agency also approved Johnson & Johnson’s Opsynvi – a single-tablet combination of macitentan and tadalafil – for the chronic treatment of adults with PAH. With this approval, Opsynvi became the only once-daily combination therapy for PAH.Apart from PAH, there was another significant approval for hypertension. FDA okayed Idorsia’s once-daily treatment Tryvio (aprocitentan) in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not able to adequately control their BP on other drugs. Idorsia’s stock was up 50 percent in March. Tryvio is the first oral anti-hypertensive therapy, which works via a new therapeutic pathway, to be approved in almost 40 years.The US agency also approved Italfarmaco Group’s oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all variants of DMD, a genetic disorder characterized by progressive muscle degeneration.Orchard Therapeutics’ Lenmeldy was also greenlit by the FDA as the first gene therapy in the US for a debilitating and rare pediatric disorder, known as metachromatic leukodystrophy (MLD).Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) Breyanzi okayed for complex leukemia; Tevimbra approved for esophageal cancerAmong cancer treatments, FDA granted an accelerated approval to BMS’ Breyanzi, making it the first and only CAR-T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). BMS’ stock was up 6 percent in March.BeiGene’s PD-1 blocker Tevimbra (tislelizumab) finally got the go ahead from the FDA as a treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.FDA also granted accelerated approval to Takeda’s Iclusig (ponatinib) to be used with chemotherapy for newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a type of blood cancer of the bone marrow and blood.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) Pfizer-Takeda’s Adcetris posts trial win in DLBCL; FDA defers donanemab approvalIn clinical trials, there was some positive news from a phase 3 trial on Pfizer and Takeda’s drug Adcetris, which is known as a standard of care in classical Hodgkin lymphoma. The med has now shown to be efficacious in diffuse large B-cell lymphoma (DLBCL), a common type of non-Hodgkin lymphoma, when used in combination with two other drugs — lenalidomide and rituximab.In a late-stage trial, Novo Nordisk’s broadly used blockbuster diabetes drug Ozempic (semaglutide) slashed the risk of kidney disease progression and death from cardiovascular or kidney complications by 24 percent in diabetic patients with CKD. In negative news from the trials, the much anticipated approval of Eli Lilly’s donanemab scheduled for March was deferred as FDA opted to convene a panel of independent experts to assess the drug’s safety and efficacy. Similarly, Amylyx’s Relyvrio (sodium phenylbutyrate and taurursodiol), a promising investigational treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, failed to demonstrate it works better than a placebo in a 48-week long trial. ALS is a fatal motor neuron disease characterized by progressive degeneration of nerve cells.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) Our viewWith so many drug approvals, March was a good month for the biopharma industry. While it may look like the markets didn’t cheer the approvals, all the three indices — the NBI, XBI, and SPSIBI — ended the quarter in the green, growing 2.1 percent, 7.3 percent, and 6.4 percent, respectively, between January 2 and March 28. As we enter the second quarter of 2024, we hope the buoyancy in drug approvals and the indices is maintained.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) 

    Impressions: 870

    https://www.pharmacompass.com/pipeline-prospector-blog/march-sees-approvals-of-pathbreaking-nash-drug-from-madrigal-two-meds-for-pah

    PharmaCompass.com
    04 Apr 2024

Weekly News Recap #Phispers

  • US panel accuses China of subsidizing fentanyl production; Nigeria introduces 5-in-1 meningitis vaccine
    This week’s news brings a mix of promising advancements and concerning issues.  A majority of opioid overdose deaths in America involve fentanyl. This week, a special House committee released a report that said the Chinese government is directly subsidizing the manufacturing and export of illicit fentanyl and other synthetic narcotics through tax rebates.Nigeria has become the first country to roll out the “revolutionary” new Men5CV vaccine against meningitis that protects against five strains of the bacteria that causes the disease, as opposed to the existing one-strain vaccines.  In regulatory news, the US Food and Drug Administration (FDA) issued India’s Natco Pharma a warning letter after it received inadequate response to its Form 483.In deals, Takeda has signed a potential US$ 1.2 billion deal with Kumquat Biosciences to develop a novel immuno-oncology candidate and AbbVie has partnered with Medincell to develop next-generation long-acting injectable therapies. Meanwhile, reports of a possible takeover of Biogaran, a subsidiary of French pharma giant Servier, has raised concerns over 8,600 production jobs.There were late-stage wins for Intra-Cellular’s Caplyta in treating major depressive disorder, Roche’s Columvi in improving survival in lymphoma patients, and Novartis’ Fabhalta in treating patients with the kidney disease IgA nephropathy (IgAN).Eli Lilly’s popular weight-loss drug Zepbound has cut episodes of irregular breathing associated with sleep apnea in two late-stage trials. And in trial losses, Sage Therapeutics said its investigational oral medicine dalzanemdor did not show statistically significant differences as compared to a placebo in Parkinson’s disease. Sage does not plan to develop dalzanemdor any further in treating Parkinson’s.China subsidizing fentanyl production to fuel US epidemic, says House panelThe Chinese Communist Party (CCP) is directly subsidizing the manufacturing and export of illicit fentanyl materials and other synthetic narcotics through tax rebates, a report by the House’s Select Committee on the CCP revealed. A months-long investigation uncovered a government website  that in turn revealed tax rebates to produce specific fentanyl precursors, so long as companies sold them outside of China. The strong synthetic opioid is commonly used to lace drugs, making them extremely dangerous. A majority of overdose deaths in the US involve fentanyl — the committee said it “kills over 200 Americans daily,” on average.Nigeria makes history by introducing five-in-one meningitis vaccineNigeria has become the first country to roll out the “revolutionary” new Men5CV vaccine against meningitis. The World Health Organization called it a historic move. The new shot protects against five meningitis strains of the meningococcal bacteria, unlike the existing one-strain vaccines. Nigeria is one of the 26 meningitis hyper-endemic countries situated in the African Meningitis Belt. Last year, there was a 50 percent jump in annual meningitis cases reported across Africa. The rollout, funded by Gavi, the vaccine alliance, aims to reach one million people.Takeda inks potential US$ 1.2 bn immuno-oncology deal with Kumquat BiosciencesJapanese drugmaker Takeda has agreed to pay Kumquat Biosciences over US$ $1.2 billion in upfront and milestone payments to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- and/or combination-therapy. Kumquat will receive up to US$ 130 million in near-term payments after it concludes phase 1 trial activities.AbbVie partners with Medincell for injectable therapies: French biopharmaceutical company Medincell will use its commercial-stage long-acting injectable technology platform to formulate up to six innovative therapies. It will receive an upfront payment of US$ 35 million and will be eligible for up to US$ 1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales.Possible takeover of Biogaran by Indian company raises concerns over 8,600 jobs French publications Les Échos and Franceinfo reported about the possible takeover of Biogaran, a top generic drugmaker in France. Biogaran, a subsidiary of the pharma giant Servier, has a portfolio of about 900 drugs, and employs subcontractors that represent about 8,600 jobs largely in France and Europe. According to the reports, among the four interested buyers are India’s Torrent Pharmaceuticals and Aurobindo Pharma. This has raised concerns about relocation of production jobs. Biogaran reportedly represents about 32 percent of the French generic market.Intra-Cellular’s Caplyta sees late-stage win for major depressive disorderIntra-Cellular Therapies said a phase 3 study of Caplyta (lumateperone) in people with major depressive disorder (MDD) met both its primary and key secondary endpoints. Given once daily as an adjunctive therapy to antidepressants, Caplyta 42 mg significantly beat the placebo at improving depression severity. An atypical antipsychotic of the butyrophenone class, Caplyta got the FDA go-ahead as a once-daily oral treatment for schizophrenia in 2019. In 2021, the approval was expanded to include bipolar depression. However, analysts say MDD’s patient population is about three times larger than bipolar depression and an expanded approval could add at least US$ 1 billion to peak sales.Zepbound reduces sleep apnea severity: Last month, FDA had approved Novo Nordisk’s weight loss drug Wegovy for lowering the risk of a stroke and heart attack in overweight and obese patients who did not have diabetes. And this month, Eli Lilly’s popular weight-loss drug Zepbound (tirzepatide) cut irregular breathing episodes associated with a common sleep-related disorder – obstructive sleep apnea (OSA). Treatment with Zepbound reduced the frequency of irregular breathing episodes by as much as 63 percent in adults with OSA and obesity across two late-stage trials. Lilly plans to submit the findings to FDA to expand Zepbound’s use for OSA.Roche’s drug improves survival in lymphoma patients: Roche’s Genentech said Columvi (glofitamab-gxbm), in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A late-stage study pitted the Columvi-chemotherapy combination against a rituximab-chemotherapy combination in patients who received at least one prior line of therapy and are not candidates for autologous stem cell transplant. Patients in the Columvi group lived longer. Genentech plans to submit the data to health authorities. An expanded label for Columvi could see it potentially challenge AbbVie and Genmab’s Epkinly (epcoritamab).Novartis lands FDA priority review for Fabhalta in IgAN: Novartis said Fabhalta (iptacopan) reduced proteinuria (protein in the urine) in patients with IgA nephropathy by 38.3 percent in a phase 3 trial. The Swiss drugmaker filed for FDA’s accelerated approval using the data, and the agency has granted it priority review.Sage scraps Parkinson’s dud after mid-stage failure: Sage Therapeutics said its investigational oral medicine dalzanemdor did not show statistically significant differences as compared to a placebo on the primary endpoint in patients with mild cognitive impairment in Parkinson’s disease. Sage does not plan to develop dalzanemdor any further in treating Parkinson’s.Natco hit with FDA warning letter, shipments to US suspendedIndia’s Natco Pharma was hit with a warning letter after an inadequate response to a Form 483. Natco has stopped making products for the US market at the facility in the Indian state of Telangana. FDA said equipment wasn’t being cleaned and maintained properly, which could have led to contamination of the medications being manufactured. Additionally, the company wasn't looking into why some batches of medicine differed from what they were supposed to be, and there were even missing records for some batches.  

    Impressions: 1107

    https://www.pharmacompass.com/radio-compass-phisper/us-panel-accuses-china-of-subsidizing-fentanyl-production-nigeria-introduces-5-in-1-meningitis-vaccine

    #Phispers by PharmaCompass
    18 Apr 2024

Content #LearnMore

  • View Sharp`s clinical trial supply & contract pharmaceutical packaging services for injectables and oral dosage forms on PharmaCompass.
    View Sharp`s clinical trial supply & contract pharmaceutical packaging services for injectables and oral dosage forms on PharmaCompass. What is pharmaceutical contract packaging and how is Sharp a reliable packaging partner for the pharmaceutical and biotech industries? Pharmaceutical packaging can be defined as a set of operations including filling, sealing, packaging, and labeling of semi-finished or finished products. Pharma packaging is an economical means to present, preserve, identify, provide information, maintain product integrity, and ensure stability. It also plays a crucial role in the transportation of sensitive and strictly controlled products. Pharmaceutical contract packaging refers to packaging that is executed and supplied by a licensed third-party service provider that comprises both initial packaging and repackaging. These contract packaging service providers may offer clinical and commercial packaging solutions for pharmaceutical products. Pharmaceutical contract packaging organizations are well-equipped to offer a comprehensive range of primary, secondary, and tertiary packaging solutions. Primary packaging surrounds the pharmaceutical formulation and includes bottles, blisterings, pouches, sachets, tubes, auto-injector pens, etc. Whereas secondary packaging offers further external protection and includes artwork design, labeling for parenteral and injectables, child-resistant and compliance prompting packaging, etc. Additionally, tertiary packaging is used during transportation to absorb physical impacts, moisture, and dust and includes cardboard boxes, stretch wraps, shrink films, and wooden and plastic pallets. Sharp is a leading contract packaging organizations that offer pharmaceutical packaging services among others. It has more than 70 years of experience in pharmaceutical clinical packaging, clinical trial supply services, and small-scale sterile manufacturing. Sharp has more than 2,000 employees who work in its state-of-the-art GMP facilities in the US, UK, Belgium, and the Netherlands. Sharp, offers contract manufacturing and packaging services and support from phase I clinical trial supplies to commercial launch and lifecycle management to its pharmaceutical and biotechnology partners across the world. It has deep expertise in clinical trial packaging and labeling along with a skilled global design team that utilizes cutting-edge software and technology ensuring patient-friendly and differentiated packaging for drug products. Apart from this, Sharp is also a reliable partner for sourcing packaging material and offers integrated pharmaceutical packaging and labeling services along with over-encapsulation of oral solids and the production of placebo capsules for study blinding. Sharp is a contract packaging organization that offers commercial packaging services including contract blister packaging services, bottle packaging, sachet packaging, injectable packaging, and other solid dose packaging solutions. Additionally, it offers clinical packaging and labeling solutions such as clinical trial material packaging, clinical trial packaging and labeling, clinical trial logistics and packaging, and clinical trial supply services, or clinical supplies. Its clinical and commercial packaging services are outlined below: Clinical Packaging Solutions Sharps clinical packaging solutions encompass primary packaging and labeling and secondary packaging. Its pharmaceutical primary packaging offers reliable clinical packaging services, clinical supply chain services, primary packaging solutions, and cold-chain secondary packaging and labeling at 2-8°C, -20°C, and even at -70°C. Sharp also provides reliable clinical pharma packaging services and labeling, secondary packaging solutions, pharmaceutical clinical packaging and labeling solutions along with expertise and capabilities in handling cold-chain pharmaceutical labeling and packaging from 2-8°C to -70°C. Commercial Packaging Solutions For more than 65 years, Sharp has been providing a full range of commercial primary and secondary packaging solutions, blister packaging, and contract manufacturing and packaging services for pharmaceutical oral solid dosage forms. It offers contract blister packaging services and bottle packaging for pharmaceutical drug products. Apart from this Sharp provides pharma packaging contract services for small and large-volume batch sizes of injectables. It offers pharmaceutical packaging services for cold chain storage, packaging in temperature- and light-controlled environments, serialization, and customized distribution. Additionally, Sharp is involved in the pharma packaging of oral solids, liquids, and semi-solids. Moreover, Sharp is a premier commercial packaging service provider for high-value, low-volume gene therapy. It also offers pharmaceutical packaging services, expertise, and powerful technology that facilitates product serialization and aggregation. Therefore, Sharp’s pharma packaging contract services, spanning from clinical supplies to commercial include pharma clinical trial material manufacturing, clinical primary packaging services, clinical secondary packaging solutions, clinical trial packaging and labeling, and clinical trial logistics and packaging. Furthermore, Sharp’s contract manufacturing and packaging services encompass commercial pharma packaging solutions and labeling and supply services. Consequently, all the aforementioned offerings position Sharp as a one-stop-shop contract pharmaceutical packaging service provider for clinical and commercial scales. How does Sharp address challenges related to clinical labeling and secondary packaging? Sharp has over 70 years of experience and is a pioneer in clinical trial supply services and pharmaceutical packaging. Dedicated to the right-first-time principle, Sharp is a reliable partner for secondary packaging and clinical pharmaceutical labeling and packaging. It offers a wide range of quick, scalable clinical trial packaging services and labeling and packaging solutions in all formats, with capabilities spanning the complete lifespan of investigational medicinal products (IMPs). Moreover, Sharp can also address challenges related to packaging and labeling and offers pharmaceutical packaging and labeling services and clinical packaging and labeling services to its clients. Additionally, its clinical packaging and labeling solutions also include in-house auxiliary variable data printing outsourced booklet labels; client-supplied randomization fully supported; and annex 13 compliant and 21 CFR Part 11 compliant PRISYM software for label design. Sharp's pharmaceutical packaging and labeling services include single and multi-panel labels and booklets; 2D barcoding capabilities, randomized and open; 128 barcoding. It also offers; regulatory and translation services; sequentially numbered, variable text; code break, and randomized generation among other clinical packaging and labeling solutions. Sharp is a leader in providing pharmaceutical clinical packaging, contract packaging services, and labeling and supply services in compliance with strict regulatory guidelines. It has special pharma packaging and labeling expertise and capabilities for packaging drug products. Sharp addresses various challenges related to pharma packaging and labeling which includes: Sharp can provide cold-chain pharmaceutical labeling and packaging from 2-8°C to -70°C for drug products that need low temperatures for their transportation and storage. Sharp can support the secondary packaging for most complex drug candidates, such as controlled substance packaging (DEA schedule I-V), and has the capabilities to scale up to commercial supplies. Its design and logistics staff can also assist with the challenges of blinding products and syringes for clinical trial services. Sharp does this by providing annex 13 compliant and 21 CFR Part 11 compliant PRISYM software for label design, client-supplied randomization fully supported, and in-house auxiliary variable data printing outsourced booklet labels. With issues related to timely delivery and efficient labeling, Sharp provides pharmaceutical labeling and packaging solutions by using Scan assembly technology and Interactive Response Technologies (IRT), storage, and distribution. To overcome the label readability issues for clients worldwide, Sharp designs and prints multilingual clinical labels. Therefore, Sharp acts as a one-stop-shop packaging organization that provides pharmaceutical contract packaging services, clinical primary packaging services, primary and secondary clinical packaging, and labeling and supply services to its clients worldwide. What range of packaging design and kitting services does Sharp offer? Sharp is a market leader in the design and delivery of primary and secondary packaging. Due to its structural, graphic, and design engineers as well as its understanding of supply chain and regulatory issues, Sharp excels in pharmaceutical packaging. Sharp has years of experience in creating cutting-edge pharma packaging solutions. It is skilled in brand creation, modifying current artwork, marketing research, FDA filing standards, 3D rendering, senior, child-friendly, or child-resistant design, and labeling and supply services. Sharp's global design team provides the creativity and accuracy required to design highly functional and compliant primary and secondary commercial and clinical pharma packaging services. Sharp offers a wide range of design services and pharmaceutical packaging solutions using the latest tools and technologies to guarantee premium and user-friendly product packaging. Additionally, it provides structural and graphic design development for quick launch and regular upgrades for commercial artwork. Sharp’s wide range of packaging design services for pharmaceutical products includes: Artwork Design Services: Sharp can provide pharma packaging contract services including customized artwork as per specific markets from initial mock-ups to product registration. Packaging Samples: Sharp’s contract pharmaceutical packaging services can create production-quality models for use in marketing presentations, human factor research, and photography that closely match the commercial package. Tray Design: Sharp precisely assesses product components to create a tray design that best suits the drug. 3D Printing: Sharp can rapidly confirm that all product components fit by using its technology to create 3D printed prototypes of trays and other packaging component designs. Shipper and Pallet Design: The structural designers at Sharp develop pallet layouts and shippers based on finished items to guarantee drug safety during distribution and storage. CR/SF Compliant Design and Testing: Sharp offers pharmaceutical contract packaging services and can determine the level of toxicity in child-friendly packaging. Various structural design services offered by Sharp include end-user interactions and compliance; child-resistant, senior-friendly (CR/SF) design; tamper evident features; multiple-component kitting requirements; and sustainable or specified materials. Additionally, Sharp’s graphic design capabilities include serialization artwork; brand identity; complete package graphics; product and package illustrations; and late-stage customization. Sharp’s broad range of tailored kitting options for medical devices, pharmaceuticals, and biotechnology calls for the packaging of multiple components into a single, self-contained unit. The design team at Sharp offers commercial packaging solutions and helps clients create a kit that best meets the end-user needs and product specifications. Its kitting services include labeling, tray packing, and boxing with comprehensive verification inspection to ensure the highest level of quality. How does Sharp manage the packaging of sterile formulations to ensure product integrity? Sharp has almost seven decades of packaging experience and it provides pharmaceutical packaging solutions for sterile and non-sterile formulations while maintaining the integrity and quality of products. It offers contract pharmaceutical packaging services and package design services from its US and EU facilities for injectables containing both small and large-volume batch sizes. For product launch and sample programs, its international design team works with clients to provide pharma packaging solutions and determine the optimal vial, prefilled syringe, and autoinjector packaging options. Through its partnership with Berkshire Sterile Manufacturing (BSM), Sharp also offers small-scale isolator-based sterile fill-finish options. It specializes in pharmaceutical clinical packaging and commercial packaging in cold chain storage, packaging in temperature and light-controlled environments, and specialty distribution for injectable drug products.  It also supports multi-country launches from the US and EU. Sharp has experience in parenteral and injectable format labeling and packaging such as vials, autoinjectors, syringes, and pens. Its specialized commercial and clinical services for injectables and parenterals include primary and secondary labeling of vials, IV bags, pre-filled syringes, and IV bottles in ambient, cold and ultra-cold environments; custom label generation; kitting; serialization and aggregation; and storage and distribution. Some of Sharp’s sterile packaging capabilities for injectable drug products include: Vial Labeling and Packaging: Sharp has decades of packaging experience and offers pharmaceutical packaging and labeling services for vials. Its contract packaging services include an automated visual inspection of labeling, tray and carton packing, cartoning of single and multipacks, tamper-evident solutions, cold-chain storage (2-8°C), and ultra-low temperature freezer banks (-20°C/-70°C). In addition to these services, Sharp provides package design; kitting; and segregated suites to handle highly potent APIs (HPAPI), cytotoxins, hormones; serialization and aggregation; and specialty distribution. Autoinjector and Pen Assembly, Labeling, and Packaging: Sharp excels in managing the complexities related to autoinjector or pen device labeling and packaging from its US and EU facilities. Moreover, its YpsoMate autoinjector device delivers a high level of technical accuracy required for the assembly of prefilled syringes into YpsoMate autoinjectors. Sharp’s experts also offer clinical trial packaging services and specialize in managing the challenges related to clinical trial logistics and packaging of biological formulations. Pre-Filled Syringe Assembly, Labeling, and Packaging: Sharp is a leader in the assembly, labeling, and packaging of pre-filled syringes and safety devices. It provides customized commercial and clinical pharma packaging services for both small and large-volume batch sizes for injectables. Small Scale Sterile Fill-Finish: Sharp partners with Berkshire Sterile Manufacturing (BSM) and offers high-quality, manufacturing, packaging, and distribution solutions for flexible fillers, BSM fills vials, cartridges, syringes, and lyophilization. Gene Therapy Clinical and Commercial Packaging: Sharp has over 70 years of experience in packaging complex pharmaceuticals such as low-volume, high-value gene therapies. Sharp is also engineered to provide demand-led supply commercial and clinical services including batch sizes as small as 1 vial, or packaging, labeling, and distribution in cold, ultra-cold, or cryogenic conditions. Sharp also has dedicated facilities in Bethlehem, PA, US, Heerenveen, and the Netherlands for handling gene therapies. These facilities are equipped with HEPA air handling systems; controlled temperature; humidity and dew point; full-sized -80°C freezer banks in dedicated production suites; constant monitoring of time-out-of-refrigeration, and specific freeze-thaw cycles. These facilities help in providing clinical trial packaging services and clinical secondary packaging solutions along with commercial packaging of sterile formulations. What range of pharmaceutical packaging solutions does Sharp offer for solid and liquid drug products? With a history spanning more than 70 years, Sharp is a pioneer in providing pharmaceutical packaging services that include primary and secondary packaging of solid, liquid, and semi-solid drug products for clinical and commercial scales from its state-of-the-art facilities. Sharp offers innovative and economical clinical packaging services for investigational medicinal products (IMP). It also supports the packaging of various dosage forms including bottling of solid formulations, and thermo and cold forming blister packaging for oral solids. Sharp also supports the packaging of powder and OSDs in sachets and pouches, oral and transdermal films in strips, and injectables in vials, syringes, and cartridges. Moreover, it is also involved in the packaging of semi-solids such as cream and ointment in tubes. Some of Sharp’s pharmaceutical packaging solutions for solid and liquid drug products are mentioned below: Bottle Packaging for Solids and Semi-solids: Sharp provides pharma packaging contract services for bottle packaging that include component sourcing, carton printing and in-line cartoning or bundling, comprehensive onsite engineering and validation support, serialization and aggregation, and strict quality control for packaged drugs. Sharp also offers high-quality nitrogen flush bottles and bottle packaging for moisture and oxygen-sensitive drugs. Blister Packaging for Oral Solids: Sharp provides various blister packaging solutions including thermoform and cold form blisters, patient packs, hospital unit dose packs, wallet cards, child-resistant lidding, sustainable foil and blister materials, and multiple products per blister. Apart from this, Sharp’s contract blister packaging services also involve multi-color foil printing, in-house tooling design and fabrication, polymer laminates (Aclar, PVC/PVDC, etc.) heat-seal coating resins, and automated visual inspection. Pouches and Sachets for Solids and Transdermal Patches (Primary and Secondary Packaging Services): Sharp has expertise in pouch and sachet packaging filled with solid dose, powder, thin film, and transdermal patch drug products. Sharp’s solid dose packaging solutions offer considerable pouch and sachet packaging backed by quality operations and project management knowledge. Sharp is home to a sizable assemblage of form, fill, and seal technologies. Based on decades of practical expertise, Sharp uses a wide range of innovative film structure materials, such as coated papers, high-barrier foils, and polymer laminates, and offers pharma packaging contract services. It also can support the production of multiple dosage forms for pharmaceutical products. Oral Thin Film and Transdermal Patches: Sharp provides primary and secondary packaging services for oral thin films and transdermal patches. Sharp specializes in die-cutting and pouching sublingual and oral dissolvable films, and transdermal drug delivery systems, and offers specialized pharmaceutical packaging services through quality procedures. It utilizes the most up-to-date solid dose packaging solutions and processes to safely package and safeguard specialty drug products. Sharp’s oral thin film and transdermal patch capabilities include highly accurate dosing by die-cutting laminated products to any size and shape; in-line printing of drug info, bar codes, lot number, expiration date, serialization with optical character verification (OCV); etc. Therefore, Sharp is a pharmaceutical contract packaging organization that offers clinical services, cold chain packaging, clinical packaging and labeling, and commercial packaging. Its pharmaceutical contract packaging service also encompasses primary and secondary clinical and commercial packaging. 

    Impressions: 219

    https://www.pharmacompass.com/pharma-blog/contract-packaging-primary-and-secondary-packaging-services-offered-by-sharp

    #LearnMore by PharmaCompass
    04 Mar 2024